Imunon Past Earnings Performance

Past criteria checks 0/6

Imunon's earnings have been declining at an average annual rate of -11.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 24.1% per year.

Key information

-11.5%

Earnings growth rate

29.2%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-24.1%
Return on equity-483.3%
Net Marginn/a
Next Earnings Update07 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Imunon makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:CBO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-18811
31 Mar 240-19812
31 Dec 230-201011
30 Sep 230-281112
30 Jun 230-311312
31 Mar 230-311414
31 Dec 221-361412
30 Sep 221-27120
30 Jun 221-26110
31 Mar 221-26110
31 Dec 211-21110
30 Sep 211-20100
30 Jun 211-2290
31 Mar 211-2290
31 Dec 201-2180
30 Sep 201-2270
30 Jun 201-1970
31 Mar 201-2080
31 Dec 191-1780
30 Sep 191-890
30 Jun 191-790
31 Mar 191-10100
31 Dec 181-12100
30 Sep 181-2290
30 Jun 181-2380
31 Mar 181-206-3
31 Dec 171-2160
30 Sep 171-2164
30 Jun 171-2268
31 Mar 171-21615
31 Dec 161-22715
30 Sep 161-22615
30 Jun 161-20613
31 Mar 161-21714
31 Dec 151-22715
30 Sep 151-23716
30 Jun 151-26817
31 Mar 151-27817
31 Dec 141-25915
30 Sep 141-23812
30 Jun 141-20710
31 Mar 141-1379
31 Dec 131-1379

Quality Earnings: CBO is currently unprofitable.

Growing Profit Margin: CBO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CBO is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.

Accelerating Growth: Unable to compare CBO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: CBO has a negative Return on Equity (-483.32%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies